Bridging EGFR/TGF-β signaling to bypass resistance to immune checkpoint blockade.

IF 10.2 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2025-09-23 DOI:10.1158/1078-0432.ccr-25-2727

Noura J Choudhury,Aditi Kothari,Christine M Bestvina,Natalia Issaeva

引用次数: 0

Abstract

Although EGFR is a common target in squamous cancers, anti-EGFR monotherapies have shown modest success due to existing or acquired activation of other oncogenic pathways and tumor heterogeneity. A bifunctional fusion protein ficerafusp alfa in combination with pembrolizumab represents a potential solution to overcome resistance in early phase clinical investigation.

查看原文本刊更多论文

桥接EGFR/TGF-β信号以绕过免疫检查点阻断的抗性。

虽然EGFR是鳞状癌的常见靶点，但由于现有或获得的其他致癌途径的激活和肿瘤异质性，抗EGFR单药治疗已显示出适度的成功。在早期临床研究中，双功能融合蛋白ficerafusp alfa联合派姆单抗代表了克服耐药性的潜在解决方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.